India — Vitamins, Minerals, Proteins, and Unconventional Dietary Specialties for Humans — Herbals-Botanicals

← back to leaderboard

India received 180 FDA import refusals in Herbals-Botanicals, part of Vitamins, Minerals, Proteins, and Unconventional Dietary Specialties for Humans between 2023-Q4 and 2026-Q3. Volume peaked at 25 in 2026-Q3, with the trend roughly flat year-on-year. The most-cited issues are unapproved, salmonella, and mfr inj. No trade baseline is published for this commodity from India, so no per-$1B rate is shown here.

Of these, 41 were hazard refusals and 139 were paperwork refusals.

Exporting from India? Get an email when shipments from India are refused at the US border — before your buyers ask.

Quarterly rejections, last 12 quarters

9 2023-Q4 2023-Q4: 9 15 2024-Q1 2024-Q1: 15 13 2024-Q2 2024-Q2: 13 12 2024-Q3 2024-Q3: 12 12 2024-Q4 2024-Q4: 12 18 2025-Q1 2025-Q1: 18 15 2025-Q2 2025-Q2: 15 19 2025-Q3 2025-Q3: 19 13 2025-Q4 2025-Q4: 13 18 2026-Q1 2026-Q1: 18 11 2026-Q2 2026-Q2: 11 25 2026-Q3 2026-Q3: 25

Recent rejections